Article
19 Aug 2026
Psychedelic Therapeutics Take Center Stage: FDA Announces Public Hearing And Finalizes Clinical Guidance
AUTHORS CONTENT
Article
09 Jul 2026
FDA Proposes To Eliminate "Adequate Provision" For Broadcast Prescription Drug Advertising
Article
23 Apr 2026
CMS And FDA Announce RAPID Coverage Pathway To Accelerate Medicare Coverage For Breakthrough Medical Devices
Article
08 Apr 2026
Executive Order Imposing Section 232 Tariffs On Pharmaceuticals And Pharmaceutical Ingredients
Article
24 Nov 2025
FDA Leadership Outlines "Plausible Mechanism" Pathway For Bespoke Therapies
Article
06 Oct 2025
What The October 1, 2025 Federal Government Shutdown Means For HHS Operations
Article
30 Sep 2025
100% U.S. Tariff On Branded/Patented Drugs Effective October 1, 2025
Article
12 Sep 2025
HHS And FDA Attempt To Crackdown On Deceptive DTC Rx Drug Advertising Following Presidential Memo
Article
12 Aug 2025
FDA Launches PreCheck Program To Accelerate Onshoring Of Drug Manufacturing Facilities
Article
06 May 2025
Ingredient Source Now Or Pay Later: State Ingredient Bans Bring More Accountability To Distributors And Retailers, Not Just Manufacturers
Article
23 Apr 2025
U.S. Department Of Commerce Investigates Possible Tariffs On Pharmaceuticals: Forecasting The Impact And An Opportunity To Comment
Article
04 Apr 2025
HHS Under The Second Trump Administration
Article
11 Mar 2025
Department Of Health And Human Services Seeks To Revise Rulemaking Policies
Article
12 Feb 2025
FDA Finalizes Guidance On Scientific Information On Unapproved Uses (SIUU) Communications
Article
12 Nov 2024
What President-Elect Trump's Victory Means For Healthcare In 2025
Article
14 Aug 2024
Fostering More Access To Medical Devices: FDA's Efforts To Advance Health Equity
Article
23 Jul 2024
Loper Bright's Implications For The Food And Drug Administration And Regulated Industry
Article
15 Jul 2024
Want To Say It Ain't So? FDA Guides Firms On How To Respond To Misinformation
Article
13 Jul 2024
Action Plans On Diversity: Key Requirements For Certain Clinical Studies
Article
26 Jun 2024
States Wade Into FDA Regulatory Territory To Address Chemicals In Foods And Personal Care Products